Skip to main content
. 2018 Aug 2;10(8):257. doi: 10.3390/cancers10080257

Table 1.

Clinical backgrounds of the patients.

Total patients number 242
Gender Male: 214, Female: 28
Age 55–92 (median: 77) y.o
Performance status (ECOG) PS 0, 1, 2, 3, 4, NA * = 99, 114, 20, 2, 0, 7
Histology squamous cell cancer: 92
adenocarcinoma: 77
unspecified non-small cell lung cancer: 18
unproven: 55
Tumor size 3–50 mm (median: 27 mm)
T stage (7th UICC) T1, T2 = 160, 82
Medical operability operable:54, inoperable:175, NA *: 13
Smoking history (+): 153, (−): 25, NA *: 64
Pulmonary emphysema (+): 87, (−): 118, NA *: 37
Steroid administration before SBRT (+): 20, (−): 174, NA *: 50
% vital capacity (% VC) 45.6–150.6% (mean: 91.9%)
FEV1.0% ** 37.1–97.1% (mean: 67.9%)
SBRT dose 40–70 Gy in 4–10 fractions
V20 *** 1.1–21.7% (mean: 6.6%)

* NA: not assigned; ** FEV1.0%: percentage of predicted forced expiratory volume in one second; *** V20: rate of the volume irradiated with 20 Gy or more to the normal lung volume. (+): present; (−): absent.